256 related articles for article (PubMed ID: 11429694)
1. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
[TBL] [Abstract][Full Text] [Related]
2. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
3. Identification of Shc docking site on Ret tyrosine kinase.
Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
[TBL] [Abstract][Full Text] [Related]
4. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
[TBL] [Abstract][Full Text] [Related]
5. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.
Durick K; Gill GN; Taylor SS
Mol Cell Biol; 1998 Apr; 18(4):2298-308. PubMed ID: 9528800
[TBL] [Abstract][Full Text] [Related]
6. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
7. The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain.
Ishiguro Y; Iwashita T; Murakami H; Asai N; Iida K; Goto H; Hayakawa T; Takahashi M
Endocrinology; 1999 Sep; 140(9):3992-8. PubMed ID: 10465268
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
10. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
Besset V; Scott RP; Ibáñez CF
J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
[TBL] [Abstract][Full Text] [Related]
11. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
Knauf JA; Kuroda H; Basu S; Fagin JA
Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
[TBL] [Abstract][Full Text] [Related]
12. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
[TBL] [Abstract][Full Text] [Related]
13. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
[TBL] [Abstract][Full Text] [Related]
14. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
15. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
Asai N; Murakami H; Iwashita T; Takahashi M
J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
[TBL] [Abstract][Full Text] [Related]
16. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
Hayashi H; Ichihara M; Iwashita T; Murakami H; Shimono Y; Kawai K; Kurokawa K; Murakumo Y; Imai T; Funahashi H; Nakao A; Takahashi M
Oncogene; 2000 Sep; 19(39):4469-75. PubMed ID: 11002419
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
18. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.
Lorenzo MJ; Gish GD; Houghton C; Stonehouse TJ; Pawson T; Ponder BA; Smith DP
Oncogene; 1997 Feb; 14(7):763-71. PubMed ID: 9047383
[TBL] [Abstract][Full Text] [Related]
19. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
20. Differential interaction of Enigma protein with the two RET isoforms.
Borrello MG; Mercalli E; Perego C; Degl'Innocenti D; Ghizzoni S; Arighi E; Eroini B; Rizzetti MG; Pierotti MA
Biochem Biophys Res Commun; 2002 Aug; 296(3):515-22. PubMed ID: 12176011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
